Search | Clinical Trials Finder

Conditions: Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Double-Expressor Lymphoma, EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified, Neoplastic Cells With Double Expression of MYC and BCL2 Proteins Present, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions: Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Lumbar Puncture, Positron Emission Tomography, Prednisone, Rituximab, Venetoclax, Vincristine Sulfate; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 80 Years
Enrollment: 363 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 634
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 433 more

Conditions: End Stage Renal Disease (ESRD), Vascular Access Complication
Interventions: Single Application of Adipose Derived Mesenchymal Stem Cells (AMSC), Placebo, Two Applications of Adipose Derived Mesenchymal Stem Cells (AMSC); Biological · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 85 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Cirrhosis
Interventions: Transcutaneous Electrical Acustimulation (TEA), Sham Transcutaneous Electrical Acustimulation (TEA); Device
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Ann Arbor, Michigan • Philadelphia, Pennsylvania

Conditions: Diffuse Large B Cell Lymphoma, Post Transplant Lymphoproliferative Disorder, Primary Mediastinal (Thymic) Large B-cell Lymphoma
Interventions: DA-EPOCH-R for DLBCL, PTLD, AND PMBCL, Methotrexate, Etoposide, Doxorubicin, Vincristine, Rituximab, Cyclophosphamide, Prednisone, G-CSF; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: Up to 30 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Kidney Transplant, Type 1 Diabetes
Interventions: Alpha 1-Antitrypsin, Islet Transplantation, Thymoglobulin, Basiliximab, Etanercept; Drug · Procedure
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 70 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Overweight, Obesity
Interventions: Phone-based sessions (28 total) on a structured schedule, Phone-based sessions upon request, Weight self-monitoring, Dietary and physical activity self-monitoring, Scheduled tailored interventionist feedback, Dietary goals, Meal replacements, Physical activity goals, Toolbox, Challenges, Tailored interventionist feedback upon request; Behavioral
Lead sponsor: University of Tennessee; Other
Eligibility: 18 Years and older
Enrollment: 248 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Erectile Dysfunction
Interventions: Sildenafil Cream, Placebo Cream, Penile Plethysmography (RigiScan); Drug · Device
Lead sponsor: Strategic Science & Technologies, LLC; Industry
Eligibility: 18 Years to 70 Years · Male only
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 3
States / cities: San Diego, California • New Orleans, Louisiana • New York, New York

Conditions: Obesity, Infertility
Interventions: Estradiol, Gonadotropin-releasing hormone (GnRH), Progesterone; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 42 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Infantile Spasms
Interventions: GWP42003-P; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 1 Month to 24 Months
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 6
States / cities: Little Rock, Arkansas • Winston-Salem, North Carolina • Columbus, Ohio + 3 more

Conditions: Healthy Study Participants
Interventions: midazolam, metformin, bupropion, fenfluramine HCl; Drug
Lead sponsor: UCB BIOSCIENCES, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Gastroesophageal Adenocarcinoma
Interventions: Nivolumab 240 MG; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 5
States / cities: Tampa, Florida • St Louis, Missouri • Omaha, Nebraska + 2 more

Conditions: Healthy Adults
Interventions: Sitravatinib 50 mg, Sitravatinib 100 mg, Itraconazole, Rifampin; Drug
Lead sponsor: Mirati Therapeutics Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Multiple Myeloma
Interventions: Cevostamab, Tocilizumab, Pomalidomide, Daratumumab, Dexamethasone; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 6
States / cities: Duarte, California • Irvine, California • Denver, Colorado + 3 more

Conditions: Hypotension
Interventions: Attending real-time decision support, In-room real-time decision support, Attending feedback emails, In-room provider feedback emails, Anesthesia Information Management System (AIMS), Perioperative Data Warehouse (PDW), General anesthesia, Pager system, Central neuraxial anesthesia, Non-cardiac surgery, Propofol, Sevoflurane, Desflurane, Isoflurane, Ephedrine, Phenylephrine, Norepinephrine, Epinephrine, Dobutamine, Dopamine, Isoproterenol, Milrinone, Atropine, Glycopyrrolate, Vasopressin, Terlipressin, Sodium Chloride 0.9%, Ringer's lactate, Hydroxyethyl starch solutions, Fresh Frozen Plasma, Packed Red Blood Cells, Albumin solutions, Plasma-Lyte, Lidocaine, Bupivacaine, Levobupivacaine, Ropivacaine, Mepivacaine, Tetracaine, Prilocaine, Procaine, Chloroprocaine, Benzocaine, Articaine; Procedure · Device · Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 60 Years to 100 Years
Enrollment: 22,435 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Healthy Participants
Interventions: AZD4144- Part A, Placebo- Part A, AZD4144- Part B, Placebo- Part B, Rosuvastatin and Furosemide- Part C, Rosuvastatin, Furosemide, and AZD4144 Part C; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 91 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Glendale, California • Brooklyn, Maryland

Conditions: Coronary Artery Disease, Vascularization
Interventions: Acceptance and commitment therapy; Behavioral
Lead sponsor: University of Iowa; Other
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Chronic Plaque Psoriasis
Interventions: Bimekizumab; Drug
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 2
States / cities: High Point, North Carolina • Bexley, Ohio

Conditions: Ankylosing Spondylitis
Interventions: 150 mg open-label secukinumab, 150 mg double-blinded secukinumab, 300 mg double-blinded secukinumab; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 322 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 65
States / cities: Jonesboro, Arkansas • Fullerton, California • Loma Linda, California + 60 more

Conditions: Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7
Interventions: Docetaxel, Durvalumab, Laboratory Biomarker Analysis; Drug · Biological · Other
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 993
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 623 more

Conditions: Schizophrenia
Interventions: Placebo, bitopertin [RO4917838] level 1, bitopertin [RO4917838] level 2; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 604 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 22
States / cities: Costa Mesa, California • Escondido, California • Granada Hills, California + 19 more

Conditions: Myelodysplastic Syndromes, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Acute Leukemia, Multiple Myeloma
Interventions: Rituximab, Conditioning chemotherapy, TMS, FLAG, EPOCH-F, Hematopoietic stem cell transplant, Palifermin, Acetaminophen, Diphenhydramine, Prednisone, Epinephrine, IV Saline, ECG, ECHO, MUGA, DEXA, CT chest, PET, MRI, BM aspirate, BM biopsy, Lumbar puncture; Biological · Drug · Procedure + 2 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2025
U.S. locations: 2
States / cities: Bethesda, Maryland • Minneapolis, Minnesota

Conditions: Gallbladder Cancer
Interventions: irinotecan hydrochloride; Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2001
U.S. locations: 20
States / cities: Scottsdale, Arizona • Peoria, Illinois • Urbana, Illinois + 17 more

Conditions: Relapsing Multiple Sclerosis
Interventions: Ofatumumab, [F-18]PBR06; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 60 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Visual Field Defect, Peripheral, Stroke, Visual Impairment, Hemianopsia, Quadrantanopia, Cortical Blindness, Visual Field Defect Homonymous Bilateral, Occipital Lobe Infarct, Visual Fields Hemianopsia
Interventions: transcranial random noise stimulation (tRNS), Computer Based Visual Training, Sham stimulation, Virtual Reality Based Visual Training; Device · Behavioral
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas

Autologous Adipose Derived Mesenchymal Stem Cells (AMSC) in Reducing Hemodialysis Arteriovenous Fistula Failure

Chronic Pain Optimization and Management for Relief and Functionality With TEA in Cirrhosis

Dose Adjusted EPOCH-R, to Treat Mature B Cell Malignancies

Multicenter Trial of the Effect of AAT on Islet Transplant Engraftment and Durability After Renal Transplant

Dissemination of the Look Ahead Weight Management Treatment in the Military

Phase 2a Topical Sildenafil Proof-of-Concept Study in Men With Mild to Moderate ED

Estrogen Sensitivity and Ovulatory Dysfunction in Obesity

Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms (GWPCARE7)

A Study to Assess Drug-drug Interaction of ZX008 in Healthy Male and Female Study Participants

Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol CA209-76L)

PK Study to Assess Drug-drug Interaction Between Sitravatinib and a P-gp Inducer and an Inhibitor.

A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma

Decision Support for Intraoperative Low Blood Pressure

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 as Well as the Impact of AZD4144 on the Pharmacokinetics of Rosuvastatin and Furosemide in Healthy Participants

Acceptance and Commitment Therapy for Patients Undergoing Coronary Artery Bypass Graft Surgery

A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Adult Patients With Chronic Plaque Psoriasis

Study Estimating the Clinical Difference Between 300 mg and 150 mg of Secukinumab Following Dose Escalation to 300 mg in Patients With Ankylosing Spondylitis

Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers

A Study of RO4917838 (Bitopertin) in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (WN25305)

Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

Irinotecan in Treating Patients With Advanced Gallbladder or Bile Duct Cancer

9-month Study to Assess the Efficacy of Ofatumumab on Microglia in Patients With Relapsing Forms of Multiple Sclerosis

Improving Visual Field Deficits With Noninvasive Brain Stimulation